ClinicalTrials.gg
CompletedNCT00043758Updated Jun 24, 2005

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

A Phase 2 interventional study of Tolvaptan in Congestive Heart Failure, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 40 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Enrollment
4th of 19
170 · median 60
Started
2002
with 1 other
Phase 2
4 of 19
none open now
Registered
1st of 19
by date
Lead sponsor
5 of 19
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 19 studies testing tolvaptan in Heart Failure, this one is the 4th largest by enrollment, is one of 2 that started in 2002, is one of 4 in phase 2, and was the 1st registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

The purpose of this study is to study the effects of tolvaptan on the size and function of the left heart chamber (ventricle) in patients with congestive heart failure (CHF)

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

Keywords

  • CHF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

History of congestive heart failure

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
170 participants

Interventions

06

Study locations

40 sites
  • Desert Cardiology of Tucson
    Tucson, Arizona 85741, United States
  • Arkansas Heart
    Little Rock, Arkansas 72211, United States
  • San Diego Cardiac Center
    San Diego, California 92123, United States
  • Northern California Medical Associates
    Santa Rosa, California 95403, United States
  • Cardiovascular Consultants Medical Group, Inc.
    Walnut Creek, California 94598, United States
  • University of Colorado
    Denver, Colorado 80262, United States
  • The Hoffman Heart Institute of CT/St. Francis Hospital
    Hartford, Connecticut 06105, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Cardiology Associates of Fort Lauderdale
    Fort Lauderdale, Florida 33308, United States
  • Cardiovascular Research Center of South Florida
    Miami, Florida 33173, United States
  • Charlotte Heart Group
    Port Charlotte, Florida 33952, United States
  • The Heart and Vascular Institute of Florida
    St. Petersburg, Florida 33701, United States
  • Cardiovascular Associates of Augusta, PA
    Augusta, Georgia 30901, United States
  • Georgia Heart Specialists
    Covington, Georgia 30014, United States
  • Illinois Heart and Lung Associates, SC
    Normal, Illinois 61761, United States
  • The Care Group, LLC
    Indianapolis, Indiana 46260, United States
  • Medical Research Institute
    Slidell, Louisiana 70458, United States
  • Androscoggin Cardiology Associates
    Auburn, Maine 04210, United States
  • Maine Cardiology Associates
    Portland, Maine 04102, United States
  • Pentucket Medical Associates
    Haverhill, Massachusetts 01839, United States
  • Mystic Cardiology Associates, Inc.
    Medford, Massachusetts 02155, United States
  • Harper Hospital/Wayne State University
    Detroit, Michigan 48201, United States
  • John Dingell VA Medical Center
    Detroit, Michigan 48201, United States
  • St. Luke's-Roosevelt Hospital Center
    New York, New York 10025, United States
  • South Bay Cardiovascular Associates
    West Islip, New York 11795, United States
  • The Lindner Clinical Trial Center
    Cincinnati, Ohio 45219, United States
  • Midwest Cardiology Research Foundation
    Columbus, Ohio 43202, United States
  • North Ohio Research LTD
    Lorraine, Ohio 44053, United States
  • North Ohio Research LTD.
    Sandusky, Ohio 44870, United States
  • Medical College of Pennsylvania
    Philadelphia, Pennsylvania 19129, United States
  • Guthrie Clinic, LTD
    Sayre, Pennsylvania 18840, United States
  • Miriam Hospital
    Providence, Rhode Island 02905, United States
  • University Cardiology Foundation
    Providence, Rhode Island 02905, United States
  • Ralph H. Johnson VAMC
    Charleston, South Carolina 29401, United States
  • Stern Cardiovascular Center
    Memphis, Tennessee 38120, United States
  • Health Sciences Center
    Winnipeg, Manitoba R3A 1R9, Canada
  • Health Sciences Center Memorial University of Newfoundland
    St. John's, Newfoundland and Labrador A1B 3V6, Canada
  • London Health Sciences Center
    London, Ontario N6A 4G5, Canada
  • St. Michael's Hospital
    Toronto, Ontario M5B 1W8, Canada
  • The Toronto Hospital
    Toronto, Ontario M5G 2C4, Canada
07

References and documents

Publications

  • Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol. 2007 Jun 5;49(22):2151-9. doi: 10.1016/j.jacc.2007.01.091. Epub 2007 May 18. PubMed 17543634 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2002 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2002
First posted
Aug 14, 2002
Start
Jul 2002
Completion
Jul 2004
Last update
Jun 24, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00043758
First posted
Aug 14, 2002
Start date
Jul 2002
Completion
Jul 2004
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion